Alexion Pharmaceuticals Inc. shares inched 0.77% higher to $184.14 Monday. This proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.23% to 4,290.61 and the Dow Jones Industrial Average DJIA falling 0.44% to 34,283.27.Alexion Pharmaceuticals Inc. hit a new 52-week high, surpassing its previous peak of $183.05, which the company reached on June 16th. The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Gilead Sciences Inc. GILD fell 0.27% to $67.70, Vertex Pharmaceuticals Inc. VRTX rose 1.79% to $197.82, and Regeneron Pharmaceuticals Inc. REGN fell 1.43% to $542.70.
Alexion Pharmaceuticals Inc trading volume (1.1 M) remained 844,903 below its 50-day average volume of 2.0 M.This was the stock’s fourth consecutive day of gains. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor.